Hamamatsu Photonics Expands Intended Use of NanoZoomer® MD Series in Europe to Include Cytology

Hamamatsu Photonics is pleased to announce an expansion of the intended use of the NanoZoomer MD series in Europe to include cytology slide digitization. The expanded clinical application scope supports laboratories seeking greater consistency, efficiency, and diagnostic confidence in cellular image evaluation.

Image Credit: Hamamatsu Photonics Europe

Enhanced digital capabilities for cytology The expanded intended use is supported by findings from the recently published study Validation of Digital Cytology for Primary Diagnosis Across a Range of Specimen Types, conducted by researchers at University College London and University College London Hospitals NHS Foundation Trust and published in Cytopathology. With the expanded intended use, the NanoZoomer MD series in Europe can now be used to acquire digital images from a broad range of cytology preparations, including: 

  • Conventional Pap smears 
  • Liquid-based cytology samples 
  • Non-gynecological preparations 
  • Fine-needle aspirates (FNAs) 

Cytology evaluation depends on fine detail recognition, nuclear features, and subtle chromatic differences. The NanoZoomer MD series in Europe supports these needs through:

  • High-resolution optical capture for accurate visualization
  • Consistent color reproduction to support reproducible assessments
  • Automated focus and scanning stability

The result is a reliable digital environment that supports pathologists in delivering high-quality clinical evaluations. 

Enabling Laboratories in Their Digital Transformation

By incorporating cytology into its intended use, the NanoZoomer MD series in Europe gives pathology institutions the ability to:

  • Consolidate histology and cytology on a single digital platform
  • Accelerate case review and remote collaboration
  • Support long-term digital archiving strategies

Commitment to Pathology Excellence 

This expansion reflects Hamamatsu’s ongoing commitment to enabling fully digital workflows across the spectrum of pathology, including both histology and cytology, and aligns with increasing clinical demand for high-quality digital images for routine review, consultation, and archiving. 

We are proud to broaden the intended use of the NanoZoomer MD Series,” said Martin Kristensson, Strategic Marketing Manager at Hamamatsu Photonics Europe. “Cytology has been a key request from our clinical partners, and this expansion reinforces Hamamatsu’s long-standing commitment to providing high precision, clinically validated imaging solutions that meet the evolving needs of modern pathology.

References

T. Mistry, H. Hunter, D. Oukrif, S. Pomplun, R. Patel, M. Rodriguez-Justo, and A. P. Levine, “Validation of digital cytology for primary diagnosis across a range of specimen types,” Cytopathology, Mar. 10, 2026. [Online]. Available: doi:10.1111/cyt.70063

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Hamamatsu Photonics Europe. (2026, April 30). Hamamatsu Photonics Expands Intended Use of NanoZoomer® MD Series in Europe to Include Cytology. AZoNano. Retrieved on April 30, 2026 from https://www.azonano.com/news.aspx?newsID=41671.

  • MLA

    Hamamatsu Photonics Europe. "Hamamatsu Photonics Expands Intended Use of NanoZoomer® MD Series in Europe to Include Cytology". AZoNano. 30 April 2026. <https://www.azonano.com/news.aspx?newsID=41671>.

  • Chicago

    Hamamatsu Photonics Europe. "Hamamatsu Photonics Expands Intended Use of NanoZoomer® MD Series in Europe to Include Cytology". AZoNano. https://www.azonano.com/news.aspx?newsID=41671. (accessed April 30, 2026).

  • Harvard

    Hamamatsu Photonics Europe. 2026. Hamamatsu Photonics Expands Intended Use of NanoZoomer® MD Series in Europe to Include Cytology. AZoNano, viewed 30 April 2026, https://www.azonano.com/news.aspx?newsID=41671.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.